Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells

[1]  G. Schuler,et al.  Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance , 2019, Cancers.

[2]  D. Kaplan,et al.  Bioinspired Preservation of Natural Killer Cells for Cancer Immunotherapy , 2019, Advanced science.

[3]  Robin L. Jones,et al.  Optimising Cancer Vaccine Design in Sarcoma , 2018, Cancers.

[4]  J. Vose,et al.  R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis , 2018, British journal of haematology.

[5]  Qing Li.  Natural Killer (NK) Cell Assays in Immunotoxicity Testing. , 2018, Methods in molecular biology.

[6]  S. Matosevic,et al.  Natural killer-92 cells maintain cytotoxic activity after long-term cryopreservation in novel DMSO-free media. , 2017, Immunology letters.

[7]  A. Scheffold,et al.  Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders , 2017, Front. Immunol..

[8]  M. Neurath,et al.  Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis , 2017, Inflammatory bowel diseases.

[9]  Richard Gerum,et al.  ClickPoints: an expandable toolbox for scientific image annotation and analysis , 2017 .

[10]  B. Fabry,et al.  Traction Force Microscopy in 3‐Dimensional Extracellular Matrix Networks , 2017, Current protocols in cell biology.

[11]  T. D. de Gruijl,et al.  The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments , 2017, Front. Immunol..

[12]  Alexander A. Tong,et al.  Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma , 2017, Oncoimmunology.

[13]  J. Lahuerta,et al.  Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma , 2016, Oncoimmunology.

[14]  J. Madrigal,et al.  Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34(+) cells. , 2016, Cytotherapy.

[15]  Y. Naito,et al.  Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer , 2015, Journal of Translational Medicine.

[16]  Thomas Brox,et al.  U-Net: Convolutional Networks for Biomedical Image Segmentation , 2015, MICCAI.

[17]  M. Schilham,et al.  CD56(dim)CD16⁻ NK cell phenotype can be induced by cryopreservation. , 2015, Blood.

[18]  D. Schadendorf,et al.  A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma , 2015, Journal of Translational Medicine.

[19]  J. Wagner,et al.  Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  M. Mata,et al.  Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays. , 2014, Journal of immunological methods.

[21]  B. Önfelt,et al.  Distinct Migration and Contact Dynamics of Resting and IL-2-Activated Human Natural Killer Cells , 2013, Front. Immunol..

[22]  Björn Önfelt,et al.  Classification of human natural killer cells based on migration behavior and cytotoxic response. , 2013, Blood.

[23]  S. Rosenberg,et al.  Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression , 2011, Clinical Cancer Research.

[24]  D. Campana,et al.  Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity , 2010, Journal of experimental & clinical cancer research : CR.

[25]  Wei Liu,et al.  Evaluation of biodistribution and safety of adenovirus vector containing MDR1 in mice , 2010, Journal of experimental & clinical cancer research : CR.

[26]  Lai-Xi Wang,et al.  Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. , 2008, Blood.

[27]  M. Verneris,et al.  CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases , 2007, Leukemia.

[28]  Mario Roederer,et al.  Ex vivo identification, isolation and analysis of tumor-cytolytic T cells , 2003, Nature Medicine.

[29]  D. Vesole,et al.  IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial , 2003, Bone Marrow Transplantation.

[30]  W. Hiddemann,et al.  Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of Hsp70‐expressing tumors , 2000, International journal of cancer.

[31]  M. Parrini,et al.  Co-ordination and specificity of the action of GTPase-activating proteins and GDP/GTP-exchange factors on Ras. , 1997, Biochemical Society transactions.

[32]  M W Lowdell,et al.  Natural killer cell function is altered by freezing in DMSO. , 1996, Biochemical Society transactions.

[33]  J. Vliegenthart,et al.  Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity. , 1993, Journal of immunological methods.

[34]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[35]  S Marsoni,et al.  The phase II trial. , 1985, Cancer treatment reports.

[36]  S. Rosenberg.  Combined modality therapy of cancer. What is it and when does it work? , 1985, The New England journal of medicine.